DK1152012T3 - Tuberkulosevacciner - Google Patents

Tuberkulosevacciner

Info

Publication number
DK1152012T3
DK1152012T3 DK01109298T DK01109298T DK1152012T3 DK 1152012 T3 DK1152012 T3 DK 1152012T3 DK 01109298 T DK01109298 T DK 01109298T DK 01109298 T DK01109298 T DK 01109298T DK 1152012 T3 DK1152012 T3 DK 1152012T3
Authority
DK
Denmark
Prior art keywords
tuberculosis vaccines
vaccines
tuberculosis
epitopes
esat
Prior art date
Application number
DK01109298T
Other languages
English (en)
Inventor
Ajit Lalvani
Roger Hamilton Brookes
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10803428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1152012(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of DK1152012T3 publication Critical patent/DK1152012T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01109298T 1996-11-25 1997-11-25 Tuberkulosevacciner DK1152012T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method
PCT/GB1997/003222 WO1998023960A1 (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells

Publications (1)

Publication Number Publication Date
DK1152012T3 true DK1152012T3 (da) 2007-11-26

Family

ID=10803428

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01109298T DK1152012T3 (da) 1996-11-25 1997-11-25 Tuberkulosevacciner
DK97913336T DK0941478T4 (da) 1996-11-25 1997-11-25 Assaymetode for peptidspecifikke T-celler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97913336T DK0941478T4 (da) 1996-11-25 1997-11-25 Assaymetode for peptidspecifikke T-celler

Country Status (11)

Country Link
US (3) US7575870B1 (da)
EP (2) EP0941478B2 (da)
JP (1) JP4094674B2 (da)
AT (2) ATE213068T1 (da)
AU (1) AU728357C (da)
CA (1) CA2272881C (da)
DE (2) DE69710360T3 (da)
DK (2) DK1152012T3 (da)
ES (1) ES2172773T5 (da)
GB (1) GB9624456D0 (da)
WO (1) WO1998023960A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
ES2333073T3 (es) 1998-11-04 2010-02-16 Isis Innovation Limited Prueba diagnostica de tuberculosis.
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
AU2001256999A1 (en) * 2000-04-12 2001-10-30 Wisconsin Alumni Research Foundation. A method for making an hiv vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
DE10125730A1 (de) * 2001-05-17 2002-11-21 A I D Autoimmun Diagnostika Gm Verfahren zum Nachweis von Erregern und durch diese induzierten zellulär produzierten Stoffen im lebenden Organismus
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
ATE557099T1 (de) * 2003-09-05 2012-05-15 Genencor Int Hpv cd8+ t-zell-epitope
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
CN104056251B (zh) 2004-04-28 2019-09-17 英国技术集团国际有限公司 与腹部疾病有关的表位
WO2006009838A2 (en) * 2004-06-17 2006-01-26 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
GB0619853D0 (en) 2006-10-06 2006-11-15 Oxford Immunotec Ltd Preparation method
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
EP2353008A2 (en) 2008-09-22 2011-08-10 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
CN102713629B (zh) 2009-11-20 2016-02-24 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
IT1403092B1 (it) 2010-12-01 2013-10-04 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio della mucormicosi.
WO2012103315A2 (en) 2011-01-27 2012-08-02 Osa Holdings, Inc. Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
FR2983213B1 (fr) 2011-11-30 2015-03-06 Commissariat Energie Atomique Procede de mesure en temps reel des secretions individuelles d'une cellule
WO2013093512A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccine - screening method
GB201122297D0 (en) 2011-12-23 2012-02-01 Retroscreen Virology Ltd Vaccine - screening method
WO2013106338A1 (en) 2012-01-12 2013-07-18 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
JP6272820B2 (ja) * 2012-03-23 2018-01-31 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ Ｈｉｖ特異的ｔ細胞応答のモニタリング方法
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
WO2015164722A1 (en) 2014-04-24 2015-10-29 Immusant, Inc. Compositions comprising gluten
CA2962920C (en) 2014-10-01 2023-03-14 Cryosa, Llc Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
CA2968422A1 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
FR3033333A1 (fr) 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
CA3059408A1 (en) 2016-09-22 2018-04-12 Pace Diagnostics, Inc Mycobacterium tuberculosis proteins in diagnostic assays and devices for tuberculosis detection and diagnosis
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
ES2950436T3 (es) 2016-12-14 2023-10-10 Becton Dickinson Co Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto
WO2019018607A1 (en) 2017-07-20 2019-01-24 Enzo Biochem, Inc. IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
AU2019419502A1 (en) 2018-12-31 2021-07-22 Cryosa Inc. Systems and methods for treatment of obstructive sleep apnea
KR102182555B1 (ko) * 2019-03-14 2020-11-24 한국과학기술연구원 T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
US20220214332A1 (en) 2019-05-30 2022-07-07 Oregon Health & Science University Methods for Detecting A Mycobacterium Tuberculosis Infection
US12551259B2 (en) 2020-02-19 2026-02-17 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
CA3243280A1 (en) 2021-12-30 2023-07-06 Cryosa, Inc. SYSTEMS AND METHODS FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296158B1 (en) 1986-03-06 1992-06-17 Commonwealth Scientific And Industrial Research Organisation $i(IN VITRO) ASSAY FOR DETECTING CELL-MEDIATED IMMUNE RESPONSES
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US20020136733A1 (en) 1994-03-31 2002-09-26 Hill Adrian Vivian Sinton Malaria peptides
WO1997000067A1 (en) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Mycobacterium tuberculosis dna sequences encoding immunostimulatory peptides
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
GB9624456D0 (en) * 1996-11-25 1997-01-15 Isis Innovation Assay method
ES2333073T3 (es) * 1998-11-04 2010-02-16 Isis Innovation Limited Prueba diagnostica de tuberculosis.
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
EP1152012A1 (en) 2001-11-07
DE69737956D1 (de) 2007-09-06
DE69710360D1 (de) 2002-03-21
ATE213068T1 (de) 2002-02-15
EP1152012B1 (en) 2007-07-25
AU5063298A (en) 1998-06-22
ATE368052T1 (de) 2007-08-15
US9360480B2 (en) 2016-06-07
US7575870B1 (en) 2009-08-18
CA2272881A1 (en) 1998-06-04
AU728357B2 (en) 2001-01-04
DK0941478T4 (da) 2007-10-08
DE69710360T2 (de) 2002-11-14
EP0941478B1 (en) 2002-02-06
EP0941478A1 (en) 1999-09-15
CA2272881C (en) 2007-10-09
US20100203568A1 (en) 2010-08-12
AU728357C (en) 2001-11-01
ES2172773T3 (es) 2002-10-01
GB9624456D0 (en) 1997-01-15
DE69737956T2 (de) 2008-04-17
JP4094674B2 (ja) 2008-06-04
EP0941478B2 (en) 2007-06-06
US20140087399A1 (en) 2014-03-27
US8617821B2 (en) 2013-12-31
ES2172773T5 (es) 2008-01-16
JP2001505568A (ja) 2001-04-24
DK0941478T3 (da) 2002-07-01
DE69710360T3 (de) 2008-01-17
WO1998023960A1 (en) 1998-06-04

Similar Documents

Publication Publication Date Title
DK1152012T3 (da) Tuberkulosevacciner
EP0656788A4 (en) Hla binding peptides and their uses
BR9406652A (pt) Composição
EP1189624A4 (en) Hla binding peptides and their uses
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
TR199701252T1 (xx) Bir saponin ve bir sterol i�eren a��lar.
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
DE69836588D1 (de) Tuberkulose impfstoff
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20005050D0 (no) Fusjonsproteiner fra Mycobacterium Tuberculosis-antigener og deres anvendelse
KR900700607A (ko) 면역학적 주효체 세포 활성화 및 화학적 인력을 유발하는 단백질
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
GB9409985D0 (en) Vaccine against mycobacterial infections
DK1214088T3 (da) Proteiner udtrykt af Mycobacterium tuberculosis og ikke af BCG og anvendelse heraf som diagnostiske reagenser og vacciner
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
DE69525058D1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
NO20005081D0 (no) Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DK469188A (da) Fremgangsmaade og indretning til tilvejebringelse af personlig luftkonditionering
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους
KR940018852U (ko) 등산용 배낭의 에어 쿠션 장치
ID21667A (id) Komposisi ii antigen bakteri dan komposisi vaksin